This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.


Scientific Focus

Human malignancies frequently elicit specific adaptive immune responses. In the last years, numerous tumor-associated antigens recognized by CD8+ and CD4+ T cells have been identified, providing an essential knowledge for the development of T-cell based immunotherapies for cancer. The recent approval of checkpoint inhibitor antibodies and of Sipuleucel-T as immunotherapeuticals is further stimulating the entire field. But the road ahead is still arduous, and the optimal target antigens, adjuvants, as well as the strategies to circumvent T-cell tolerization are the subject of extensive research efforts.

Our aim is to contribute to the understanding of immune responses against cancer and to apply this knowledge in immunotherapy. We are focusing on the description of adaptive T-and B-immune responses in cancer patients, either before or during therapy including immunotherapy. Fine subsets of T cells are investigated at the phenotypic and functional levels. We also investigate the antibody response, as well as further immune cell subsets interacting with human tumors.

In addition, we are a founding member and co-organiser of the CIMT Immunoguiding Program (CIP). The main objective of this international working group is to evaluate, compare and improve the sensitivity and reproducibility of the techniques applied in immunomonitoring, and thus to contribute to accelerate progresses in the field.

PD Dr. Cécile Gouttefangeas

University of Tübingen
Interfaculty Institute for Cell Biology
Department of Immunology
Auf der Morgenstelle 15
D-72076 Tübingen, Germany

Phone: +49-7071-29 80994
Fax:     +49-7071-29 5653
Email:   cecile.gouttefangeas (@)